Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the Company has changed its registered address to 40 Bank Street, Floor 24, London, E14 5NR, United Kingdom.
Poolbeg Pharma relocates to new London headquarters at 40 Bank Street
- Written by: Amilia Stone
Find more news, interviews, share price & company profile here for:
Latest Company News
Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs.
Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs.
Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy.
Poolbeg Pharma's POLB 001 is an innovative, orally-administered treatment aiming to combat severe influenza and cytokine release syndrome, revolutionising immunotherapy.
Cytokine Release Syndrome (CRS) complicates cancer immunotherapy, but Poolbeg Pharma’s POLB 001 offers a groundbreaking oral solution to enhance patient outcomes.
